AEON Biopharma (AEON) Announces CEO Change
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
AEON Biopharma Announces CEO Transition
March 27, 2025 4:05 PM EDTMarc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors
Jost Fischer, Chairman of AEON, will assume the role of interim CEO
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (AEON or the Company) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to... More
